리바이브 테라퓨틱스(RVVTF)는 PINK에 상장된 Healthcare · Pharmaceuticals 기업입니다. 현재가 $0.01 (-10.27%), 시가총액 $5.42M, 52주 범위 $0.01 ~ $0.03.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.
리바이브 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
일봉 종가 기준 계산값이며 과거 성과는 미래 수익을 보장하지 않습니다.
리바이브 테라퓨틱스의 현재 주가는 $0.01 (-10.27%)입니다. XTS에서 시세와 차트를 확인할 수 있습니다.
리바이브 테라퓨틱스의 시가총액은 약 $5.42M입니다.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders.